Pleiotropic role of VEGF-A in regulating fetal pulmonary mesenchymal cell turnover

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 290, Issue 6, 2006, Pages

  Majka, S ^a,e   Fox, K ^a,b   McGuire, B ^c   Crossno Jr , J ^a,b   McGuire, P ^c   Izzo, A ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e NONE   (United States)

Author keywords

Bronchopulmonary dysplasia; Proliferation; SUGEN 5416

Indexed keywords

PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN P21; SEMAXANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL CYCLE; CELL PROLIFERATION; CELL SPREADING; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; LUNG ALVEOLUS CELL; MESENCHYME CELL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SHEEP;

ANIMALS; BASE SEQUENCE; CELL CYCLE; CELL DIVISION; DNA PRIMERS; FETUS; GENES, BCL-2; IMMUNOHISTOCHEMISTRY; LUNG; MESODERM; MICE; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; PROTO-ONCOGENE PROTEINS P21(RAS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33744818444     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00175.2005     Document Type: Article

References (54)

1. Abman S and Groothius J. Pathophysiology and treatment of BPD. Respir Med 41: 277-315, 1994.
2. Akeson AL, Wetzel B, Thompson FY, Brooks SK, Paradis H, Gendron RL, and Greenberg JM. Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme. Dev Dyn 217: 11-23, 2000.
3. Akeson A, Greenberg J, Cameron J, Thompson F, Brooks S, Wiginton D, and Whitsett J. Temporal and spatial regulation of VEGF a controls vascular patterning in embryonic lung. Dev Biol 264: 443-455, 2003.
4. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, and Carmeliet P. Role of PLGF in the intra- and intermolecular cross talk between the VEGF receptors Flt-1 and Flk1. Nat Med 9: 936-943, 2003.
5. Barazzone C, Horowitz S, Donati Y, Rodriguez I, and Piguet P. Oxygen toxicity in mouse lung: pathways to cell death. Am J Respir Cell Mol Biol 19: 573-581, 1998.
6. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, and Mercurio AM. Flt-1 dependent survival characterizes the epithelial mesenchymal transition of colonic organiods. Curr Biol 13: 1721-1727, 2003.
7. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, and Maniscalco WM. Disrupted pulmonary vasculature and decreased VEGF, Flt-1 and Tie-2 in human infants dying with BPD. Am J Respir Crit Care Med 164: 1971-1980, 2001.
8. Bonnefoy-Berard N, Aouacheria A, Verschelde C, Quemeneur L, Marcais A, and Marvel J. Control of proliferation by bcl-2 family members. Biochim Biophys Acta 1644: 159-168, 2003.
9. Borges E, Jan Y, and Ruslahti E. PDGF receptor beta and VEGFR-2 bind to the beta-3 integrin through its extracellular domain. J Biol Chem 275: 39867-39873, 2000.
10. Burridge K and Wennerberg K. Rho and Rac take center stage. Cell 116: 167-179, 2004.
11. Cantley L. The PI3 kinase pathway. Science 296: 1655-1657, 2002.
12. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, and Stoll B. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 141: 370-375, 2002.
13. Coalson J, Winter V, Siler-Khodr T, and Yoder B. Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med 160: 1333-1346, 1999.
14. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, and Carmeliet P. Loss of HIF2a and inhibition of VEGF impair fetal lung maturation whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702-710, 2002.
15. D'Angio C and Maniscalco W. The role of vascular growth factors in hyperoxia induced injury to the developing lung. Front Biosci 7: d1609-d1623, 2002.
16. Demayo F, Minoo P, Plopper CG, Schuger L, Shannon J, and Torday JS. Mesenchymal-epithelial interactions in lung development and repair: are modeling and remodeling the same process? Am J Physiol Lung Cell Mol Physiol 283: L510-L517, 2002.
17. Dziadek M, Darling P, Bakker M, Overall M, Zhang RZ, Pan TC, Tillet E, Timpl R, and Chu ML. Deposition of collagen VI in ECM during mouse embryogenesis correlates with the expression of the a3(VI) subunit gene. Exp Cell Res 226: 302-315, 1996.
18. Fong GH, Rossant J, Gertsenstein M, and Breitman ML. Role of the flt receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
19. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, and McMahon G. SU5416 is a potent selective inhibitor of the VEGF receptor (Flk/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 59: 99-106, 1999.
20. Gebb S and Shannon J. Tissue interactions mediate early events in pulmonary vasculogenesis. Dev Dyn 217: 159-169, 2000.
21. Greenberg JM, Thompson FY, Brooks SK, Shannon JM, McCormick-Shannon K, Cameron JE, Mallory BP, and Akeson AL. Mesenchymal expression of VEGF D & A defines a vascular patterning in developing lung. Dev Dyn 224: 144-153, 2002.
22. Haddad J, Choudhary K, and Land S. The ex vivo differential expression of apoptosis signaling cofactors in the developing perinatal lung. Biochem Biophys Res Commun 281: 311-316, 2001.
23. Hara A, Chapin CJ, Ertsey R, and Kitterman JA. Changes in fetal lung distension alter expression of VEGF and its isoforms in developing rat lung. Pediatr Res 58: 30-37, 2005.
24. Hipfner D and Cohen S. Connecting proliferation and apoptosis in development and disease. Nature 5: 805-816, 2004.
25. Hirashima M, Ogawa M, Nishikawa S, Matsumura K, Kawasaki K, Shibuya M, and Nishikawa S. A chemically defined culture of VEGFR2 cells derived from embryonic stem cells reveals the role of VEGFR+ in tuning the threshold for VEGF in developing EC. Blood 101: 2261-2267, 2003.
26. Ho L. BPD dysplasia and CLD of infancy. Ann Acad Med Singapore 31: 119-130, 2002.
27. Ilyin GP, Glaise D, Gilot D, Baffet G, and Guguen-Guillouzo C. Regulation and role of p21 and p27 cyclin dependent kinase inhibitors during hepatocyte differentiation. Am J Physiol Gastrointest Liver Physiol 285: G115-G127, 2003.
28. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, and Abman SH. Inhibition of angiogenesis decreases alveolization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279: L600-L607, 2000.
29. Jobe A and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723-1729, 2001.
30. Jobe A. The new BPD: an arrest of lung development. Pediatr Res 46: 641-643, 1999.
31. Karnezis A, Dorokhov M, Grompe M, and Zhu L. Loss of p27 enhances the transplantation efficiency of hepatocytes transferred into diseased livers. J Clin Invest 108: 383-390, 2001.
32. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H, and Ahmed A. Localization of PLGF in human term placenta. Growth Factors 13: 243-250, 1996.
33. Kippin T, Martens D, and van der Kooy D. P21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 19: 756-767, 2005.
34. Kotch L, Iyer N, Laughner E, and Semenza G. Defective vascularization of HIF-1a null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209: 254-267, 1999.
35. Krajewski S, Hugger A, Krajewska M, Reed J, and Mai J. Developmental expression patterns of bcl-2, bcl-x, bax, and bak in teeth. Cell Death Differ 5: 408-415, 1998.
36. Langston C, Kida K, Reed M, and Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 129: 607-613, 1984.
37. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, and Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283: L555-L562, 2002.
38. Maniscalco W, Watkins R, Pryhuber G, Bhatt A, Shea C, and Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 282: L811-L823, 2002.
39. Mantell L and Lee P. Signal transduction pathways in hyperoxia induced lung cell death. Mol Genet Metab 71: 359-370, 2000.
40. Marone M, Bonanno G, Rutella S, Leone G, Scambia G, and Pierelli L. Survival and cell cycle control in early hematopoiesis: role of bcl-2 and the cyclin dependent kinase inhibitors p27 and p21. Leuk Lymphoma 43: 51-57, 2002.
41. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, and Black SM. Expression of VEGF and its receptors is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285: L222-L231, 2003.
42. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, and Shima DT. Spatially restricted patterning cues provided by heparin binding VEGF-A controls blood vessel branching morphogenesis. Genes Dev 16: 2684-2698, 2002.
43. Sanchez-Esteban J, Wang Y, Cicchiello L, and Rubin L. Cyclic mechanical stretch inhibits cell proliferation and induces apoptosis in fetal rat lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 282: L448-L456, 2002.
44. Schachtner S, Wang Y, and Baldwin S. Qualitative and quantitative analysis of embryonic pulmonary vessel formation. Am J Respir Cell Mol Biol 22: 157-165, 2000.
45. Sousa P, Tanswell A, and Post M. Different roles for PDGFR-α and -β receptors in embryonic lung development. Am J Respir Cell Mol Biol 15: 551-562, 1996.
46. Stark A. High frequency oscillatory ventilation to prevent BPD-Are we there yet? N Engl J Med 347: 682-684, 2002.
47. Van den Bos C, Silverstetter S, Murphy M, and Connolly T. p21 rescues human mesenchymal stem cells from apoptosis induced by low density culture. Cell Tissue Res 293: 463-470, 1998.
48. Wang D, Donner D, and Warren R. Homeostatic modulation of KDR and Flt expression and VEGF mRNAs by VEGF-A. J Biol Chem 275: 15905-15911, 2000.
49. Weiguo S, Jiang Y, Lu M, and Morrisey E. Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development 129: 4831-4842, 2002.
50. Weinberger B, Laskin DL, Heck DE, and Laskin JD. Oxygen toxicity in premature infants. Toxicol Appl Pharmacol 181: 60-67, 2002.
51. Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M, and Makela TP. Vascular abnormalities and deregulation of VEGF in lkb1 deficient mice. Science 293: 1323-1326, 2001.
52. Zeng X, Gray M, Stahlman M, and Whitsett J. TGFb1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo. Dev Dyn 221: 289-301, 2001.
53. Zeng X, Wert SE, Federici R, Peters KG, and Whitsett JA. VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo. Dev Dyn 211: 215-227, 1998.
54. Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E, and Li QQ. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytoxicity in human ovarian tumor cells. Int J Oncol 25: 445-451, 2004.